Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

Far Eastern Energy Company reported for 3 months of 2023 by RAS

4/28/23 DVEC

ChZPSN-Profnasteel reported for 3 months of 2023 by RAS

4/28/23 PRFN

Rosinter Restaurants Holding reported for 3 months of 2023 by RAS

4/28/23 ROST

Nizhnekamskshina reported for 2022 according to IFRS

4/28/23 NKSH

Electrozinc reported for 3 months of 2023 by RAS

4/28/23 ELTZ

TNS Energo Kuban reported for 3 months of 2023 by RAS

4/28/23 KBSB

Seligdar reported for 2022 according to IFRS

4/28/23 SELG

Board of Directors of Nornickel recommends shareholders not to pay dividends for 2022

4/28/23 GMKN

Stavropolenergosbyt reported for 3 months of 2023 by RAS

4/28/23 STSB

LSR sales in Q1 decreased by 26% in physical terms and by 36% in monetary terms

4/28/23 LSRG